Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Bill Newell, the company's Chief Executive Officer, will deliver a presentation on Wednesday, January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET in San Francisco, CA.
The presentation will be available to view through the News & Events page in the Investor Relations section of Sutro's website at www.sutrobio.com. An archived version of the presentation will remain accessible for a minimum of 30 days following the event.
Sutro Biopharma (NASDAQ: STRO), un'azienda oncologica in fase clinica specializzata in conjugati di farmaci anticorpali (ADCs), ha annunciato la sua partecipazione alla 43° Conferenza Sanitaria Annuale J.P. Morgan. Bill Newell, l'Amministratore Delegato dell'azienda, presenterà il suo intervento mercoledì 15 gennaio 2025, alle 14:15 PT / 17:15 ET a San Francisco, CA.
La presentazione sarà disponibile per la visione attraverso la pagina News & Events nella sezione Relazioni con gli Investitori del sito web di Sutro all'indirizzo www.sutrobio.com. Una versione archiviata della presentazione rimarrà accessibile per un minimo di 30 giorni dopo l'evento.
Sutro Biopharma (NASDAQ: STRO), una empresa de oncología en etapa clínica especializada en conjugados de medicamentos anticuerpos (ADCs), ha anunciado su participación en la 43ª Conferencia Anual de Salud J.P. Morgan. Bill Newell, el Director Ejecutivo de la compañía, dará una presentación el miércoles 15 de enero de 2025, a las 14:15 PT / 17:15 ET en San Francisco, CA.
La presentación estará disponible para ver a través de la página de Noticias y Eventos en la sección de Relaciones con Inversores del sito web de Sutro en www.sutrobio.com. Una versión archivada de la presentación permanecerá accesible durante un mínimo de 30 días después del evento.
수트로 바이오파마 (NASDAQ: STRO)은 항체 약물 접합체 (ADCs)를 전문으로 하는 임상 단계의 종양학 회사로, JP모건 헬스케어 연례 콘퍼런스 제43회에 참여한다고 발표했습니다. 빌 뉴얼 CEO가 2025년 1월 15일 수요일, 오후 2시 15분 PT / 오후 5시 15분 ET에 샌프란시스코, CA에서 발표를 할 예정입니다.
발표 내용은 수트로 웹사이트의 투자자 관계 섹션 뉴스 및 이벤트 페이지를 통해 확인할 수 있습니다. 발표의 아카이브 버전은 행사 후 최소 30일간 접근 가능합니다.
Sutro Biopharma (NASDAQ: STRO), une entreprise de biopharma en phase clinique spécialisée dans les conjugués de médicaments par anticorps (ADCs), a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan sur la Santé. Bill Newell, le Directeur Général de l'entreprise, fera une présentation le mercredi 15 janvier 2025, à 14h15 PT / 17h15 ET à San Francisco, CA.
La présentation sera disponible en visionnage sur la page News & Events dans la section Relations Investisseurs du site web de Sutro à l'adresse www.sutrobio.com. Une version archivée de la présentation restera accessible pendant au moins 30 jours après l'événement.
Sutro Biopharma (NASDAQ: STRO), ein Unternehmen der klinischen Onkologie, das sich auf Antikörper-Arzneimittel-Konjugate (ADCs) spezialisiert hat, hat seine Teilnahme an der 43. Jahreskonferenz von J.P. Morgan Healthcare angekündigt. Bill Newell, der CEO des Unternehmens, wird am Mittwoch, den 15. Januar 2025, um 14:15 PT / 17:15 ET in San Francisco, CA, eine Präsentation halten.
Die Präsentation wird über die Seite „News & Events“ im Bereich „Investor Relations“ der Sutro-Website unter www.sutrobio.com verfügbar sein. Eine Archivversion der Präsentation wird mindestens 30 Tage nach der Veranstaltung zugänglich bleiben.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET in San Francisco, CA.
The presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. An archived replay will be available for at least 30 days after the event.
About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
FAQ
When is Sutro Biopharma (STRO) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will Sutro Biopharma's (STRO) J.P. Morgan Healthcare Conference presentation be available online?
Where can investors access Sutro Biopharma's (STRO) J.P. Morgan Healthcare Conference presentation?
What type of therapeutic products does Sutro Biopharma (STRO) develop?
